Metagenomi Therapeutics, Inc.

NasdaqGS:MGX Stock Report

Market Cap: US$50.1m

Metagenomi Therapeutics Future Growth

Future criteria checks 0/6

Metagenomi Therapeutics's revenue and earnings are forecast to decline at 0.4% and 6.6% per annum respectively while EPS is expected to grow by 6.3% per annum.

Key information

-6.6%

Earnings growth rate

6.32%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate-0.4%
Future return on equityn/a
Analyst coverage

Low

Last updated19 May 2026

Recent future growth updates

Analysis Article • May 14

Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results

It's shaping up to be a tough period for Metagenomi Therapeutics, Inc. ( NASDAQ:MGX ), which a week ago released some...

Recent updates

Analysis Article • May 14

Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results

It's shaping up to be a tough period for Metagenomi Therapeutics, Inc. ( NASDAQ:MGX ), which a week ago released some...
Analysis Article • Mar 16

Metagenomi, Inc.'s (NASDAQ:MGX) 26% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Metagenomi, Inc. ( NASDAQ:MGX ) shares are down a considerable 26% in the last...
Seeking Alpha • Jan 28

Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential

Summary MGX’s gene editing uses metagenomics and AI to build a “toolbox” of nucleases and base editors. Currently, their main application seems to be heading toward Hemophilia A, but even this IP is in the preclinical stages. Fortunately, MGX has a cash runway into 2027. However, the IND for MGX-001 is planned for 2026, meaning the company is still years away from FDA approval. I think the main drawback is its lack of clinical data on humans, as MGX mostly has speculative applications that could play out far into the future. I do think the stock is somewhat cheap at these levels, but it’s difficult to give it a “Buy” rating with no clinical or human data yet. Read the full article on Seeking Alpha
Analysis Article • Jan 28

The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26%

Metagenomi, Inc. ( NASDAQ:MGX ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...
Analysis Article • Jan 14

We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 10

Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry

Metagenomi, Inc. ( NASDAQ:MGX ) shareholders would be excited to see that the share price has had a great month...

Earnings and Revenue Growth Forecasts

NasdaqGS:MGX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202820-107N/AN/A1
12/31/202713-99-100-924
12/31/202612-90-78-704
3/31/202622-86-88-87N/A
12/31/202525-88-89-89N/A
9/30/202531-89-92-92N/A
6/30/202534-87-99-97N/A
3/31/202545-78-105-102N/A
12/31/202452-78-112-109N/A
9/30/202455-74-108-103N/A
6/30/202456-75-106-100N/A
3/31/202447-77-108-100N/A
12/31/202345-68-101-91N/A
9/30/202338-64-15-3N/A
6/30/202331-54-76N/A
3/31/202323-50720N/A
12/31/202217-441630N/A
12/31/20210-212124N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGX's revenue is expected to decline over the next 3 years (-0.4% per year).

High Growth Revenue: MGX's revenue is forecast to decline over the next 3 years (-0.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MGX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 01:41
End of Day Share Price 2026/06/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Metagenomi Therapeutics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yevgeniya LivshitsChardan Capital Markets, LLC
Maurice RaycroftJefferies LLC
Lut Ming ChengJ.P. Morgan